Oxford Nanopore Technologies PLC
LSE:ONT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oxford Nanopore Technologies PLC
Capital Expenditures
Oxford Nanopore Technologies PLC
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Capital Expenditures
-£45.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Oxford Biodynamics PLC
LSE:OBD
|
Capital Expenditures
-£244k
|
CAGR 3-Years
35%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Capital Expenditures
-£4.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Capital Expenditures
-£10k
|
CAGR 3-Years
48%
|
CAGR 5-Years
37%
|
CAGR 10-Years
24%
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Capital Expenditures
-£70k
|
CAGR 3-Years
45%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Capital Expenditures
-£1.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-8%
|
|
Oxford Nanopore Technologies PLC
Glance View
Oxford Nanopore Technologies PLC stands as a pioneering force in the field of genomics, transforming the landscape of DNA and RNA sequencing. Founded as a spin-off from the University of Oxford, the company gained recognition with its distinctive nanopore sequencing technology, which radically differs from traditional sequencing methods. Traditional sequencing often involves a process that can be expensive, time-consuming, and complex. However, Oxford Nanopore's approach uses tiny, porous apertures coupled with electrical signals to read genetic codes directly. This technology allows for the sequencing of long DNA strands in real-time, providing not only speed and efficiency but also the versatility to handle a wide range of samples, from environmental to clinical applications. By making sequencing more accessible and portable through their critically acclaimed MinION device, the company has managed to capture significant interest and investment from researchers across diverse scientific fields. The business model of Oxford Nanopore Technologies is built upon a strategic blend of product sales, including their sequencing devices and associated consumables, alongside providing commercial sequencing services. Their revenue streams are anchored by the MinION, GridION, and PromethION devices, each catering to varied throughput needs and scales of operation. Sales of these devices are complemented by a continuous income from consumable sales, essential for each sequencing run, which helps to embed their technology deeply within the workflows of their users. Additionally, the company's expansion into data analysis services further diversifies their income, utilizing their specialized expertise to assist customers in interpreting and utilizing complex genomic data. This multifaceted approach not only solidifies their position in the genomics market but also ensures multiple pathways for generating sustained revenue growth.
See Also
What is Oxford Nanopore Technologies PLC's Capital Expenditures?
Capital Expenditures
-45.7m
GBP
Based on the financial report for Dec 31, 2025, Oxford Nanopore Technologies PLC's Capital Expenditures amounts to -45.7m GBP.
What is Oxford Nanopore Technologies PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-12%
Over the last year, the Capital Expenditures growth was 6%. The average annual Capital Expenditures growth rates for Oxford Nanopore Technologies PLC have been -3% over the past three years , -12% over the past five years .